FDA grants breakthrough therapy designation to Neuraptive’s NTX-001
The FDA has granted breakthrough therapy designation to Neuraptive Therapeutics’ NTX-001 for peripheral nerve injury requiring repair.
The FDA has granted breakthrough therapy designation to Neuraptive Therapeutics’ NTX-001 for peripheral nerve injury requiring repair.
What's Your Reaction?
